美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

2倍做多NVO ETF-Defiance

17.59

+2.8919.66%

盘后：19.191.60+9.10%19:59 EST

成交量：101.75万

成交额：1,713.04万

市值：5,097.76万

市盈率：- -

高：17.61

开：16.70

低：16.36

收：14.70

52周最高：105.60

52周最低：14.59

股本：289.81万

流通股本：279.81万

量比：0.62

换手率：36.36%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

行业研究 | 2026 年 FDA 多肽新药展望：6 款潜力产品引领行业破局

诺和诺德市值蒸发4500亿美元，遭遇六个月来最差单周表现

受诺和诺德法律威胁，Hims & Hers早盘大跌6.5%

环球市场播报

财报季｜减重药物下半场：药王易主、定价压力与渗透为王

动脉新医药

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/NVOX"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"2倍做多NVO ETF-Defiance","latestPrice":17.59,"timestamp":1770411600000,"preClose":14.7,"halted":0,"volume":1017450,"hourTrading":{"tag":"盘后","latestPrice":19.19,"preClose":17.59,"latestTime":"19:59 EST","volume":60982,"amount":1153960.0371,"timestamp":1770425948484,"change":1.6,"changeRate":0.090961,"amplitude":0.127914},"delay":0,"changeRate":0.19659863945578235,"floatShares":2798101,"shares":2898100,"eps":0,"marketStatus":"休市中","change":2.89,"latestTime":"02-06 16:00:00 EST","open":16.7,"high":17.61,"low":16.36,"amount":17130440.38545,"amplitude":0.085034,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":14.7,"sharesOutstanding":2818101,"nav":14.67,"aum":41341541.67,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":16.73,"preClose":14.7,"latestTime":"09:29 EST","volume":114049,"amount":1878015.002162,"timestamp":1770388174508,"change":2.03,"changeRate":0.138095,"amplitude":0.034694},"postHourTrading":{"tag":"盘后","latestPrice":19.19,"preClose":17.59,"latestTime":"19:59 EST","volume":60982,"amount":1153960.0371,"timestamp":1770425948484,"change":1.6,"changeRate":0.090961,"amplitude":0.127914},"volumeRatio":0.6174747072051386,"impliedVol":0.8418,"impliedVolPercentile":0.524},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","floatShares":2798101,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6174747072051386,"shares":2898100,"dividePrice":0,"high":17.61,"amplitude":0.085034,"preClose":14.7,"low":16.36,"week52Low":14.5902,"pbRate":"--","week52High":105.6,"institutionHeld":0,"latestPrice":17.59,"eps":0,"divideRate":0,"volume":1017450,"delay":0,"ttmEps":0,"open":16.7,"prevYearClose":21.89,"prevWeekClose":28.89,"prevMonthClose":28.89,"prevQuarterClose":21.89},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-12-09","symbol":"NVOX","defaultRemindTime":1765290600000,"type":"split","dateTimestamp":1765256400000,"forFactor":8,"toFactor":1,"ratio":8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOX\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609543571","title":"行业研究 | 2026 年 FDA 多肽新药展望：6 款潜力产品引领行业破局","url":"https://stock-news.laohu8.com/highlight/detail?id=2609543571","media":"多肽圈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609543571?lang=zh_cn&edition=fundamental","pubTime":"2026-02-07 09:00","pubTimestamp":1770426012,"startTime":"0","endTime":"0","summary":"过去一年里，所谓的 “Tide” 军团中仅有四款新药获得 FDA 批准，而其中的主角并非多肽，而是寡核苷酸。该药于 2025 年 9 月获得 FDA 加速批准，用于改善 Barth 综合征患者的肌力，也由此成为这一病种的首个获批治疗选择。2025 年更像是一个多肽药物的“调整期”，而非真正的高光时刻。从 FDA 已披露的新药审评进度来看，一批多肽类 NCE 以及以多肽为关键驱动的产品形态，已经接近关键节点。FDA已受理其NDA并给出2026年8月28日的PDUFA目标日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207093559a6dd821e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207093559a6dd821e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4116","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4585","BK4007","BK4532","LU0154236417.USD","BK4023","BK4588","IE00BKVL7J92.USD","NVOH","LU1093756325.SGD","BK4599","NVOX","NVO"],"gpt_icon":1},{"id":"2609513560","title":"诺和诺德市值蒸发4500亿美元，遭遇六个月来最差单周表现","url":"https://stock-news.laohu8.com/highlight/detail?id=2609513560","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609513560?lang=zh_cn&edition=fundamental","pubTime":"2026-02-07 01:14","pubTimestamp":1770398053,"startTime":"0","endTime":"0","summary":"尽管周五股价小幅反弹，该股仍难逃六个月来的最差单周表现。自 2024 年 6 月市值触及 6590 亿美元峰值后，诺和诺德多年来的惊人涨幅化为乌有。诺和诺德将欧唐静的有效成分司美格鲁肽重新研发，打造出专用于减肥的维格卫，并于 2021 年 6 月获得美国监管机构批准上市，推动公司股价一路飙升。原本，维格卫口服版的上市被视为诺和诺德巩固竞争优势的契机，公司股价 1 月的反弹也创下五个月来最大涨幅。诺和诺德发布声明时，其股价盘中跌幅已达 10%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207011701a4857ae1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207011701a4857ae1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756168.USD","NVOH","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4532","BK4588","BK4585","LU1093756325.SGD","BK4599","NVOX","LU0154236417.USD","NVO","BK4007"],"gpt_icon":1},{"id":"2609597670","title":"受诺和诺德法律威胁，Hims & Hers早盘大跌6.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609597670","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609597670?lang=zh_cn&edition=fundamental","pubTime":"2026-02-06 23:38","pubTimestamp":1770392280,"startTime":"0","endTime":"0","summary":"　　受诺和诺德发出法律威胁影响，远程医疗企业 Hims & Hers 的股价在本周五早盘交易中走低。　　消息传出后，Hims 的股价在周四的交易中一度飙升 15%，但在诺和诺德指认该行为 “涉嫌违法” 后，股价迅速回吐涨幅，最终收跌 3.8%，创 12 个月新低；本周五早盘交易中，其股价再度下跌 6.5%。而诺和诺德则认为该行为涉嫌违法，且会对患者的用药安全构成风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-06/doc-inhkxcfv7812382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["NVOH","NVOX","LU1093756325.SGD","IE00BKVL7J92.USD","BK4599","BK4585","BK4007","BK4588","IE00BZ1G4Q59.USD","NVO","HIMS","LU0154236417.USD","BK4532","LU1093756168.USD"],"gpt_icon":1},{"id":"2609393567","title":"财报季｜减重药物下半场：药王易主、定价压力与渗透为王","url":"https://stock-news.laohu8.com/highlight/detail?id=2609393567","media":"动脉新医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609393567?lang=zh_cn&edition=fundamental","pubTime":"2026-02-06 18:46","pubTimestamp":1770374793,"startTime":"0","endTime":"0","summary":"近日，随着诺和诺德与礼来双双发布2025年财报，司美格鲁肽与替尔泊肽“药王”争夺故事正在进入新章节。减重药物的战场，可能已从争夺王座的单品对决，进入渗透为王、差异化制胜的“下半场”。2025年药王已易主，礼来的替尔泊肽以约365.07亿美元的全年销售额超越诺和诺德的司美格鲁肽，登顶全球药品销售榜首。2026年1月10日，其上市申请已获中国国家药监局药品审评中心受理。截至2026年1月23日，这种新型片剂的周处方量已达约5万。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206190143a484630d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206190143a484630d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4231","IE00BZ1G4Q59.USD","BK4588","LU1093756325.SGD","NVOH","BK4532","IE00BKVL7J92.USD","LLY","NVOX","LU0154236417.USD","BK4599","NVO","BK4007","LU1093756168.USD","BK4585","BK4080"],"gpt_icon":1}],"pageSize":4,"totalPage":12,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NVOX\",params:#limit:6,delay:false,,,undefined,":[]}}